

CLAIM AMENDMENTS

Claims 97-98 (**Cancelled**)

100. 99. **(Amended)** A composition comprising an anti-diabetic agent other than insulin, a bioavailable source of chromium, and a bioavailable source of vanadium, wherein said anti-diabetic agent is a sulfonylurea, and wherein components of said composition synergistically reduce the HbA1c levels of a patient by at least about 10% after treatment for a period of at least about thirty days with said composition as compared to treatment with said anti-diabetic agent alone. The composition of claim 97, wherein said anti-diabetic agent comprises a type of anti-diabetic agent selected from the group consisting of thiazolidinediones, sulfonylureas, benzoic acid derivatives, and alpha-glucosidase inhibitors.

Claims 100-102 (**Cancelled**)

104. 103. **(Amended)** The composition according to claim 10399, wherein said sulfonylurea is one of the following: acetohexamide, chlorpropamide, tolazimide, tolbutamide, glycazide, glipizide, glyburide, or glimeperide.

Claims 104-114 (**Cancelled**)

116. 115. **(Amended)** A method for improving glucose metabolism, comprising treating a patient for at least about a thirty day period by administering a pharmaceutical composition comprising an anti-diabetic agent other than insulin, a bioavailable source of chromium, and a bioavailable source of vanadium, wherein said anti-diabetic agent is a sulfonylurea, and wherein said components of said composition synergistically reduce the Hb1AeHbA1c level for of said patient is reduced by at least about 10% after such treatment as compared to treatment with said anti-diabetic agent alone.

Claims 116-133 (**Cancelled**)